Oncternal Therapeutics, Inc. Overview
Pro stress-test →Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class, novel therapies targeting a broad spectrum of cancers with large unmet medical need. The company maintains a focused pipeline despite recent divestitures, signaling a strategic pivot toward higher-conviction programs.
Strategic Profile
Pro stress-test →The company's pipeline includes zilovertamab (ROR1-targeting monoclonal antibody), ONCT-216 (ETS-family transcription factor inhibitor), ONCT-808 (ROR1-targeting CAR-T), and ONCT-534 (dual-action androgen receptor inhibitor). In July 2025, Oncternal sold its zilovertamab and ONCT-808 programs to Ho'ola Therapeutics for a $3.0 million upfront payment, reflecting a shift to earlier-stage development programs.
Competitive Landscape
Pro stress-test →Oncternal competes in the crowded clinical-stage oncology space against better-capitalized competitors pursuing ROR1, ETS, and AR inhibitor targets. Direct competitors include Jounce Therapeutics, Ayala Therapeutics, and larger biopharmaceuticals with established oncology franchises. The company's capital constraints and recent asset sales position it as a mid-to-late stage player with limited resources.
Industry Context
Oncternal Therapeutics, Inc. operates in Clinical-stage oncology drug development.
Key facts
Founded: 2013 · Headquarters: San Diego, US · Employees: 12 · Revenue: $0 (pre-revenue) · Market cap: N/A